OBJECTIVE: The authors assessed the efficacy of clozapine monotherapy
for adults with treatment-resistant obsessive-compulsive disorder. METHOD:
Twelve adults with refractory obsessive-compulsive disorder participated in
a 10-week, open-label, systematic trial of clozapine. They were assessed
with the Yale-Brown Obsessive Compulsive Scale, the Hamilton Depression
Rating Scale, and the global improvement item of the Clinical Global
Impression (CGI) scale. RESULTS: None of the 10 patients who completed the
trial was a responder. No significant change was observed in
obsessive-compulsive or depressive symptoms or in scores on the CGI global
improvement item. CONCLUSIONS: These findings suggest that clozapine
monotherapy is not effective for most adult patients with
treatment-resistant obsessive-compulsive disorder.
Abstract Teaser